Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

CompletedOBSERVATIONAL

Enrollment

9,968

Participants

Timeline

Start Date

July 26, 2013

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tofacitinib (Xeljanz)

5 mg Tablet BID

DRUG

Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc

Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly

Trial Locations (1)

Tokyo